Documente Academic
Documente Profesional
Documente Cultură
The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/121/12/1432
Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.
Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints
Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/
Vascular Medicine
B Vitamins and the Risk of Total Mortality and
Cardiovascular Disease in End-Stage Renal Disease
Results of a Randomized Controlled Trial
Judith Heinz, MSc; Siegfried Kropf, PhD; Ute Domrose, MD; Sabine Westphal, MD;
Katrin Borucki, MD; Claus Luley, MD; Klaus H. Neumann, MD; Jutta Dierkes, PhD
BackgroundIn observational studies, hyperhomocysteinemia has been found to be a risk factor for total mortality and
cardiovascular events in patients with end-stage renal disease. These patients have grossly elevated homocysteine levels
that can be lowered by supplementation with folic acid and vitamin B12. We conducted a randomized clinical trial with
B vitamins to reduce homocysteine levels and therefore cardiovascular events and total mortality.
Methods and ResultsThis randomized, double-blind multicenter study was conducted in 33 dialysis centers in north and
east Germany between July 2002 and July 2008. We randomly assigned 650 patients with end-stage renal disease who
were undergoing hemodialysis to 2 postdialysis treatments: 5 mg folic acid, 50 g vitamin B12, and 20 mg vitamin B6
(active treatment) or 0.2 mg folic acid, 4 g vitamin B12, and 1.0 mg vitamin B6 (placebo) given 3 times per week for
an average of 2 years. The primary outcome was total mortality; the secondary outcome was fatal and nonfatal
cardiovascular events. The primary outcome occurred in 102 patients (31%) receiving the active treatment and in 92
(28%) receiving placebo (hazard ratio, 1.13; 95% confidence interval, 0.85 to 1.50; P0.51). The secondary outcome
occurred in 83 patients (25%) receiving the active treatment and in 98 (30%) receiving placebo (hazard ratio, 0.80; 95%
confidence interval, 0.60 to 1.07; P0.13).
ConclusionsIncreased intake of folic acid, vitamin B12, and vitamin B6 did not reduce total mortality and had no
significant effect on the risk of cardiovascular events in patients with end-stage renal disease.
Clinical Trial RegistrationURL: www.anzctr.org.au. Unique identifier: ACTRN12609000911291. URL:
www.cochrane-renal.org. Unique identifier: CRG010600027.
(Circulation. 2010;121:1432-1438.)
Key Words: B vitamins cardiovascular diseases hemodialysis homocysteine kidney
mortality prevention
DOI: 10.1161/CIRCULATIONAHA.109.904672
1432
Downloaded from http://circ.ahajournals.org/
by guest on September 11, 2014
Heinz et al
tion or fortification. We therefore conducted a randomized
clinical trial to see whether homocysteine-lowering therapy
with folic acid, vitamin B12, and vitamin B6 could reduce total
mortality and cardiovascular events in patients with ESRD
treated with hemodialysis.
Methods
Study Design
The objective of this double-blind, placebo-controlled, randomized
multicenter trial was to see whether therapy with homocysteinelowering B vitamins could reduce total mortality and the risk of
cardiovascular events in patients with ESRD. The trial design and the
baseline data were reported recently.18 The study was conducted in
dialysis centers in north and east Germany between July 2002 and
July 2008. It was coordinated by the Institute of Clinical Chemistry
at the Otto-von-Guericke University in Magdeburg, Germany, and
sponsored by the School of Medicine at that university, Roche
Diagnostics (Mannheim, Germany; laboratory measurements), and
Fresenius Medical Care (Bad Homburg, Germany; study drug and
matching placebo). The sponsors were not involved in the design,
execution, analysis, or reporting of the results of this study. Safety of
the intervention and scientific integrity of the study were supervised
by an independent data and safety monitoring board. The study was
approved by the ethics committees of the School of Medicine of
Otto-von-Guericke University Magdeburg and the appropriate medical associations in the respective federal states of Germany. All
patients gave informed consent.
Study Population
Men and women between 20 and 80 years of age with ESRD treated
for at least 1 month by hemodialysis were enrolled, regardless of
their homocysteine levels. The exclusion criteria were acute coronary events within 6 weeks before randomization, active malignant
tumor, pregnancy, lactation, and addiction to drugs or alcohol.
Patients who had been taking vitamins before recruitment were
included after a washout phase of at least 8 weeks. The patients, who
came from 33 dialysis centers in Germany, had been put on
hemodialysis because of diabetic nephropathy (n184), chronic
glomerulonephritis (n140), interstitial nephropathy (n84), polycystic nephropathy (n75), vascular nephropathy (n63), other
reasons (n56), and unknown reasons (n48). Reason for referral to
hemodialysis was not a criterion for inclusion or exclusion.
Intervention
Patients were randomized to 2 treatment groups. Each patient
received vitamins with an originally assigned code number. The code
numbers were kept within the central pharmacy of the university
hospital. All study investigators, staff, and participants were blinded
to the randomization procedure and treatment assignments.
One tablet contained either 2.5 mg folic acid, 25 g cobalamin,
and 10 mg vitamin B6 (active treatment) or 0.1 mg folic acid, 2 g
cobalamin, and 0.5 mg vitamin B6 (placebo). After each dialysis
session (usually 3 times per week), 2 tablets were taken orally
under the supervision of a nurse. The active treatment and the
placebo tablets were custom made for this study, were outwardly
indistinguishable, and contained 6 other water-soluble vitamins in
similar concentrations, usually in amounts similar to the recommended daily allowance for adults. The exact vitamin content is
given elsewhere.18 The placebo contained vitamins to prevent
vitamin deficiencies in patients assigned to the placebo group on
the one hand and to avoid an influence on homocysteine levels on
the other hand. This approach had been tested in a clinical study
with different multivitamin tablets.19 The amounts of vitamins in
the tablets were controlled annually by an independent pharmaceutical laboratory.
1433
Trial Outcomes
The primary outcome was total mortality. The secondary outcome
was the occurrence of the first fatal or nonfatal cardiovascular event
(myocardial infarction, unstable angina pectoris, coronary vascularization procedures, sudden cardiac death, stroke, peripheral artery
disease, pulmonary embolism, and thromboses). Shunt thromboses
were not regarded as an end point.
Deaths were confirmed by hospital discharge summaries, autopsy
reports, or the responsible physicians. Causes of death were categorized as cardiac (myocardial infarction, sudden cardiac death, pulmonary edema), vascular (stroke, pulmonary embolism, thromboses,
mesenterial infarction, rupture of an aortic aneurysm), sepsis and
infections, tumors, and other causes (consequences of surgery, fluid
overload and withdrawal from dialysis, cirrhosis of the liver,
cachexia, diabetic complications, accidents, suicides, shunt complications, gastrointestinal bleeding, cerebral hemorrhage, hyperkalemia). In 15 cases, the causes of death could not be established and
were recorded as unknown.
Cardiovascular events were identified by a review of patients
medical records and by consultation with the responsible physicians. Myocardial infarction was diagnosed if at least 2 of the
following criteria had been fulfilled according to standard procedures: clinical status, elevated laboratory parameters (myocardium-specific enzymes, myoglobin), and changes in the ECG.
Catheterization was performed in cases of suspected myocardial
infarction or unstable angina pectoris. Surgical revascularization was
carried out after myocardial infarction, in unstable angina pectoris, or
when clinical signs had been detected by catheterization and the
patients general conditions permitted surgery. Strokes and ischemic
insults were verified by computed tomography. Peripheral artery
disease was diagnosed according to the Fontaine stages or on the
basis of 50% stenoses detected angiographically or sonographically in major arteries and lower limbs. Follow-up and the assigned
treatment were continued in all participants who experienced a
secondary outcome event.
Statistical Analysis
The required number of patients was calculated as 350 per treatment
group on the basis of an annual mortality of 16% and a 30%
mortality reduction as a result of the active treatment. A 1-year
recruitment phase and a study period of 3 years were assumed, with
an annual dropout rate of 10%, 2-sided type I error of 5% (adjusted
for 1 interim analysis), and a type II error of 20%.21 Because of the
1434
Circulation
Results
Compliance, Follow-Up, and Adverse Events
Between July 2002 and November 2006, a total of 650
patients were included in the trial from 33 dialysis centers in
Germany and were assigned at random to the 2 treatment
arms. The median duration of follow-up was 2.1 years (5th to
95th percentiles, 0.2 to 5.2 years). Of the 650 patients, 107
received a transplant, 75 withdrew from participation during
the trial, and 18 discontinued treatment because of a change
in dialysis center (Figure 1).23
No serious adverse events relating to the study intervention
were reported. Fifteen patients discontinued the treatment
because of intolerance of the vitamins. The disorders reported
included gastrointestinal discomfort, skin rashes, and headaches. Patients who did not continue the therapy until the end
of the study for the reasons mentioned above were included in
the final analysis with data censored at the time of the last
follow-up visit.
Baseline Characteristics
Figure 1. Trial flow diagram according to Consolidated Standards of Reporting Trials (CONSORT) Statement 2001.23
Heinz et al
Table 1.
1435
Characteristic
Total
(n650)
Placebo
(n323)
Active Treatment
(n327)
Age, y
6113
6113
6113
379 (58)
189 (59)
190 (58)
275
275
275
262 (40)
123 (38)
139 (43)
5.7 (4.97.8)
5.7 (4.77.7)
5.8 (4.97.9)
576 (89)
278 (86)*
298 (91)*
Systolic BP, mm Hg
135 (100170)
130 (95180)
136 (102169)
Diastolic BP, mm Hg
80 (6090)
80 (6090)
80 (6090)
312 (48)
149 (46)
163 (50)
619
307
312
Never
278 (45)
133 (43)
145 (46)
Former
237 (38)
122 (40)
115 (37)
Current
104 (17)
52 (17)
52 (17)
HbA1c
Hypertension, n (%)
Dialysis-related parameters
Time since dialysis, mo
32 (5166)
31 (5152)
32 (5171)
13.5 (9.016.5)
13.5 (9.016.5)
12.5 (9.016.5)
Erythropoietin, n (%)
530 (82)
269 (83)
261 (80)
193 (30)
96 (30)
97 (30)
29.0 (14.163.3)
28.2 (13.062.0)
30.0 (14.965.3)
Laboratory measurements
Homocysteine, mol/L
Folate, nmol/L
14.1 (6.675.6)
13.8 (6.867.5)
14.3 (6.384.1)
1758 (7077399)
1859 (7067128)
1716 (7047605)
Cobalamin, pmol/L
344 (154932)
351 (167908)
334 (148994)
PLP, nmol/L
22.9 (6.6192.8)
23.7 (7.3187.2)
21.4 (5.5197.4)
Creatinine, mol/L
Albumin, g/L
CRP, mg/L
CRP 5 mg/L, n (%)
809273
795290
823256
38.8 (33.143.6)
38.6 (33.144.0)
39.0 (33.143.4)
5.9 (0.742.7)
5.7 (0.640.0)
6.2 (0.649.3)
355 (55)
171 (53)
184 (56)
4.9 (3.27.2)
4.9 (3.16.9)
4.9 (3.37.3)
0.9 (0.51.5)
0.9 (0.51.5)
0.9 (0.51.6)
2.9 (1.54.8)
2.8 (1.44.8)
2.9 (1.64.8)
Triglycerides, mmol/L
2.3 (0.96.1)
2.3 (0.95.9)
2.3 (0.96.7)
HbA1c indicates hemoglobin A1c; BP, blood pressure; CVD, cardiovascular disease; RBC, red blood cell; PLP,
pyridoxal-5-phosphate; CRP, C-reactive protein; HDL, high-density lipoprotein; and LDL, low-density lipoprotein. Data are
given as meanSD, medians (5th to 95th percentiles), or numbers and percentages as appropriate.
*P0.04 for the comparison with placebo.
Discussion
The association of high homocysteine levels with the risk of
mortality and cardiovascular disease is an attractive explanation for the elevated risk in hemodialysis patients because
almost every patient exhibits elevated homocysteine levels.
Patients with ESRD show the highest homocysteine concen-
1436
Circulation
Table 2. Plasma Levels of Total Homocysteine, Serum Levels of Folate, Serum Levels of Cobalamin, and Plasma
Levels of PLP at Baseline and After 6 Months in a Subgroup of 97 Patients
Baseline
At 6 mo
P, Baseline vs 6 mo*
Changes During 6 mo
28.8 (14.168.2)
22.3 (9.854.1)
0.07
28.7 (16.569.4)
18.8 (7.233.6)
0.001
P (placebo vs treatment)
0.49
1.8 (42.315.05)
10.4 (35.82.5)
0.03
0.001
Folate, nmol/L
Placebo (n37)
11.8 (5.761.4)
15.0 (8.283.6)
12.7 (5.7118.5)
81.8 (34.0117.4)
0.05
3.0 (22.916.4)
0.001
66.4 (2.0105.8)
P (placebo vs treatment)
0.35
0.001
Placebo (n38)
288 (140690)
399 (227731)
0.001
125 (158372)
279 (72999)
407 (1631058)
0.001
100 (225459)
0.001
Cobalamin, pmol/L
P (placebo vs treatment)
0.45
0.87
0.36
Placebo (n38)
20.6 (9.9135.5)
22.1 (8.0284.0)
0.53
0.4 (58.0218.7)
26.0 (8.8333.6)
80.5 (14.1305.7)
0.001
58.4 (238.9259.3)
P (placebo vs treatment)
0.35
0.001
PLP, nmol/L
0.001
Table 3. Primary and Secondary Outcomes in the Treatment Groups, Respective Causes of Mortality, Individual Cardiovascular End
Points, and the Corresponding HRs With 95% CIs
Active Treatment
(n327), n (%)
Placebo
(n323), n (%)
Crude HR
(95% CI)
Adjusted* HR
(95% CI)
102 (31)
92 (28)
1.13 (0.851.50)
0.51
1.14 (0.851.52)
0.37
83 (25)
98 (30)
0.80 (0.601.07)
0.13
0.79 (0.591.07)
0.13
Primary outcome
Total mortality
Secondary outcome
Cardiovascular events
Category of causes of mortality
Cardiac causes
37 (11)
32 (10)
1.18 (0.731.89)
0.50
1.26 (0.772.06)
0.36
Vascular causes
6 (2)
10 (3)
0.61 (0.221.68)
0.34
0.51 (0.181.42)
0.20
28 (9)
22 (7)
1.30 (0.742.27)
0.36
1.19 (0.672.10)
0.55
8 (2)
7 (2)
1.17 (0.433.23)
0.76
1.44 (0.504.17)
0.50
14 (4)
15 (5)
0.95 (0.461.97)
0.89
1.00 (0.482.11)
0.99
9 (3)
6 (2)
1.56 (0.564.39)
0.40
1.74 (0.614.98)
0.31
0.99
20 (6)
19 (6)
1.06 (0.571.99)
0.86
1.00 (0.531.88)
8 (2)
18 (6)
0.44 (0.191.02)
0.06
0.44 (0.191.03)
0.06
5 (2)
15 (5)
0.32 (0.120.89)
0.03
0.32 (0.120.89)
0.03
22 (7)
24 (7)
0.93 (0.521.66)
0.81
1.04 (0.571.91)
0.89
11 (3)
15 (5)
0.74 (0.341.62)
0.45
0.73 (0.331.60)
0.43
26 (8)
34 (11)
0.74 (0.451.24)
0.26
0.77 (0.461.31)
0.34
7 (2)
6 (2)
1.16 (0.393.44)
0.79
1.14 (0.373.48)
0.82
*Cox regression analysis adjusted for age, sex, diabetes mellitus, hypertension, time on dialysis, C-reactive protein, and albumin.
Heinz et al
1437
infarction and 0.90 (95% CI, 0.58 to 1.40) for stroke in 2056
patients with ESRD or chronic kidney disease in HOST. In a
recent meta-analysis, we calculated for a 5-mol/L increase
in homocysteine an increase in risk of 9% for cardiovascular
events in patients with ESRD.15 If we apply this result to the
homocysteine levels obtained at 6 months in our study (Table
2), then a small, insignificant reduction in cardiovascular
disease events is plausible.
Concerning mortality, the results of our study are comparable to the results of HOST. We did not observe any effect
on specific causes of death. Regarding cardiovascular events,
analysis of specific events showed a significant reduction in
unstable angina pectoris and fewer vascularization procedures (Table 3). Because this is a post hoc analysis, the results
must be considered carefully.
The results of the present study and of other controlled
randomized trials in patients with (end-stage) renal disease
suggest that B vitamins do not have an effect on total
mortality in this population.25,26 However, there is a consistent between-trial reduction in relative risk of cardiovascular
disease, on the order of 10%. The trials conducted so far,
including ours, have been too small to establish a significant
effect of this magnitude. Doing so would require a trial with
2700 patients in each treatment group. It is not likely that an
investigation on this scale will ever be conducted to prove
this statement. The traditional approaches that have been
successful in cardiovascular disease risk reduction in patients
without renal disease are, however, ineffective in patients
with ESRD.27
A major criticism of vitamin supplementation trials in
patients without renal disease is that homocysteine is normal
or nearly normal in these patients. The median baseline
homocysteine level in our study was 28 mol/L, about twice
the value of the homocysteine levels in these trials. Whether
a similar effect would be observed in patients without renal
disease but with homocysteine levels of this magnitude
remains unknown.
Conclusions
Active treatment with folic acid, vitamin B12, and vitamin B6
did not significantly reduce total mortality and cardiovascular
risk in patients with ESRD. Our findings do not support the
administration of high-dose vitamin supplements in this total
population. However, in accordance with other studies with B
vitamins in patients with chronic kidney failure, a smaller
protective effect of the vitamins on cardiovascular events is
possible.
Acknowledgments
We are indebted to all participating dialysis patients, physicians, and
dialysis staff. None of these people received any compensation for
their contribution.
Sources of Funding
This work was funded by the School of Medicine of Otto-von-Guericke
University Magdeburg; Roche Diagnostics, Mannheim, Germany (laboratory measurements); and Fresenius Medical Care, Bad Homburg,
Germany (study drug and matching placebo).
1438
Circulation
Disclosures
None.
References
1. Vollset SE, Refsum H, Tverdal A, Nygrd O, Nordrehaug JE, Tell GS,
Ueland PM. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin
Nutr. 2001;74:130 136.
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative
assessment of plasma homocysteine as a risk factor for vascular disease.
JAMA. 1995;274:1049 1057.
3. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic
heart disease and stroke: a meta-analysis. JAMA. 2002;288:20152022.
4. Baker F, Picton D, Blackwood S, Hunt J, Erskine M, Dyas M. Blinded
comparison of folic acid and placebo in patients with ischemic heart
disease: an outcome trial. Circulation. 2002;106:3642. Abstract.
5. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC,
Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine
in patients with ischemic stroke to prevent recurrent stroke, myocardial
infarction, and death: the Vitamin Intervention for Stroke Prevention
(VISP) randomized controlled trial. JAMA. 2004;291:565575.
6. Bnaa KH, Njlstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T,
Wang H, Nordrehaug JE, Arnesen E, Rasmussen K, for the NORVIT
Trial Investigators. Homocysteine lowering and cardiovascular events
after acute myocardial infarction. N Engl J Med. 2006;354:1578 1588.
7. Ebbing M, Bleie , Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE,
Refsum H, Pedersen EK, Nygrd O. Mortality and cardiovascular events
in patients treated with homocysteine-lowering B vitamins after coronary
angiography: a randomized controlled trial. JAMA. 2008;300:795 804.
8. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen
MJ, Probstfield J, Fodor G, Held C, Genest J Jr, for the Heart Outcomes
Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering
with folic acid and B vitamins in vascular disease. N Engl J Med.
2006;354:15671577.
9. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular
disease in chronic renal disease. J Am Soc Nephrol. 1998;9:S16 S23.
10. Ikizler TA. Epidemiology of vascular disease in renal failure. Blood Purif.
2002;20:6 10.
11. Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in
chronic kidney disease. Nephron Clin Pract. 2005;101:c47 c52.
12. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP,
Neumann KH, Luley C. Cardiac troponin T predicts mortality in patients
with end-stage renal disease. Circulation. 2000;102:1964 1969.
13. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M,
Seyoum E, Hartman W, Prior R, Wilson PW, Selhub J. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage
renal disease patients on dialysis: a case-control study. Atherosclerosis.
1995;114:93103.
14. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:
386 389.
15. Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine as a risk factor for
cardiovascular disease in patients treated by dialysis: a meta-analysis.
Am J Kidney Dis. 2009;54:478 489.
16. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M,
Wojcik J, Kletzmayr J, Enzenberger B, Janata O, Winkelmayer WC, Paul
G, Auinger M, Barnas U, Horl WH. Effect of high dose folic acid therapy
on hyperhomocysteinemia in hemodialysis patients: results of the Vienna
multicenter study. J Am Soc Nephrol. 2000;11:1106 1116.
17. Dierkes J, Domrose U, Ambrosch A, Bosselmann HP, Neumann KH,
Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol. 1999;51:
108 115.
18. Heinz J, Domrose U, Luley C, Westphal S, Kropf S, Neumann KH,
Dierkes J. Influence of a supplementation with vitamins on cardiovascular
morbidity and mortality in patients with end-stage renal disease: design
and baseline data of a randomized clinical trial. Clin Nephrol. 2009;71:
363365.
19. Dierkes J, Domrose U, Bosselmann KP, Neumann KH, Luley C. Homocysteine lowering effect of different multivitamin preparations in patients
with end-stage renal disease. J Ren Nutr. 2001;11:6772.
20. Vester B, Rasmussen K. High performance liquid chromatography
method for rapid and accurate determination of homocysteine in plasma
and serum. Eur J Clin Chem Clin Biochem. 1991;29:549 554.
21. OBrien PC, Fleming TR. A multiple testing procedure for clinical trials.
Biometrics. 1979;35:549 556.
22. Andersen PK, Gill RD. Coxs regression model counting process: a large
sample study. Ann Stat. 1982;10:1100 1120.
23. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised
recommendations for improving the quality of reports of parallel-group
randomised trials. Lancet. 2001;357:11911194.
24. Frei U, Schober-Halstenberg. Nierenersatztherapie in Deutschland:
Bericht uber Dialysebehandlung und Nierentransplantation in Deutschland 2006/2007. QuaSi-Niere gGmbH 2008.
25. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R,
Atkins RC, Nicholls K, Fraenkel M, Hutchison BG, Walker R, McNeil
JJ. Cardiovascular morbidity and mortality in the Atherosclerosis and
Folic Acid Supplementation Trial (ASFAST) in chronic renal failure:
a multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;
47:1108 1116.
26. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino
PD, Gaziano JM, for the Veterans Affairs Site Investigators. Effect of
homocysteine lowering on mortality and vascular disease in advanced
chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007;298:11631170.
27. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E,
for the German Diabetes and Dialysis Study Investigators. Atorvastatin in
patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl
J Med. 2005;353:238 248.
CLINICAL PERSPECTIVE
We studied the effect of homocysteine-lowering treatment with B vitamins in patients with end-stage renal disease in a
randomized controlled trial. After each dialysis session, patients received either a high-dose vitamin supplement (active
treatment: 5 mg folic acid, 50 g vitamin B12, and 20 mg vitamin B6) or a low-dose vitamin supplement to avoid vitamin
deficiencies (control: 0.2 mg folic acid, 4 g vitamin B12, and 1 mg vitamin B6). Homocysteine concentrations were
significantly lowered in the group receiving high amounts of vitamins. Patients were followed up for a median period of
25 months. The vitamin treatment did not affect total mortality (hazard ratio, 1.13; 95% confidence interval, 0.85 to 1.50;
P0.51) or cardiovascular morbidity (hazard ratio, 0.80; 95% confidence interval, 0.60 to 1.07; P0.13). Adjustment for
other risk factors did not change these results substantially. In this randomized clinical trial, a significant clinical benefit
of additional amounts of B vitamins for lowering of homocysteine concentrations was not shown. The results are in
accordance with other trials that used B vitamins in patients with renal disease.
Page 72
Rsums darticles
Antcdents parentaux daccident vasculaire crbral
et risque dAVC encouru par les enfants
LEtude de Framingham
Sudha Seshadri, MD ; Alexa Beiser, PhD ; Aleksandra Pikula, MD ; Jayandra J. Himali, MSc ;
Margaret Kelly-Hayes, DEd, RN ; Stephanie Debette, MD, PhD ; Anita L. DeStefano, PhD ;
Jose R. Romero, MD ; Carlos S. Kase, MD ; Philip A. Wolf, MD
ContexteLes donnes sur le lien existant entre les antcdents parentaux daccident vasculaire crbral (AVC) et le risque de
survenue dun tel vnement chez les enfants sont tonnamment divergentes, cela tenant en grande partie lhtrognit des
protocoles dtudes et labsence dinformations valides, contrairement au statut des ascendants en matire dAVC pour lequel
on dispose de donnes historiques.
Mthodes et rsultatsNous avons men une tude en milieu communautaire pour savoir si la survenue dun AVC chez un parent
(documente sur un mode prospectif) avait eu ou non pour effet daccrotre le risque encouru par ses enfants de prsenter un tel
accident ; pour ce faire, parmi les participants ltude de Framingham sur la descendance, nous avons constitu une cohorte de
3 443 individus initialement sans antcdent dAVC (53 % de femmes ; ge moyen : 48 14 ans) mais dont un parent avait t
victime dun tel vnement (avant lge de 65 ans) et qui staient prts aux premier, troisime, cinquime et/ou septime
examens prvus, ces sujets ayant t suivis pendant 8 ans aprs le bilan initial. Sur plus de 11 029 priodes dobservation
individualise (soit 77 534 annes-patients), nous avons recens 106 AVC parentaux survenus avant lge de 65 ans et 128 ayant
frapp la descendance (respectivement 74 et 106 de ces accidents ayant t de type ischmique). Par lemploi de modles de Cox
multivaris ajusts pour lge, le sexe, la place dans la fratrie et les facteurs de risque dAVC initialement prsents, nous avons
tabli que la survenue, chez un ascendant, dun quelconque type dAVC et, notamment, dun accident dorigine ischmique avait
concouru augmenter le risque de survenue du mme type dAVC chez les enfants (rapport de risques : 2,79 ; intervalle de
confiance [IC] 95 % : 1,68 4,66 ; p <0,001 pour lanalyse portant sur les AVC de tous types ; rapport de risques : 3,15 ; IC
95 % : 1,69 5,88 ; p <0,001 pour lanalyse portant sur les AVC de type ischmique). La corrlation sest montre valide, que
lantcdent dAVC ait t enregistr chez la mre ou chez le pre.
ConclusionsLa survenue documente dun AVC chez lun des parents avant lge de 65 ans a concouru tripler le risque
daccident du mme type chez les enfants. Cette augmentation du risque a persist aprs ajustement tenant compte des facteurs
conventionnels de risque dAVC. Les antcdents parentaux valids dAVC pourraient ds lors se rvler cliniquement utiles
pour valuer le degr dexposition dun individu donn au risque dAVC. (Traduit de langlais : Parental Occurrence of Stroke
and Risk of Stroke in Their Children The Framingham Study. Circulation. 2010;121:13041312.)
72
16:33:15:11:10
Page 72
Page 73
Rsums darticles
73
Mthodes et rsultatsCette tude multicentrique randomise et en double aveugle a t mene dans 33 centres dhmodialyse
dAllemagne du Nord et de lEst entre juillet 2002 et juillet 2008. Nous avons randomis 650 patients hmodialyss au stade
dinsuffisance rnale terminale de manire constituer deux groupes de traitement qui ont respectivement reu, 3 fois par
semaine pendant une dure moyenne de 2 ans, 5 mg dacide folique, 50 g de vitamine B12 et 20 mg de vitamine B6 (groupe de
traitement actif) ou 0,2 mg dacide folique, 4 g de vitamine B12 et 1,0 mg de vitamine B6 (groupe placebo). Le critre de
jugement principal a t la mortalit globale, le critre secondaire ayant t le taux dvnements cardiovasculaires fatals et non
fatals. Lvnement cible principal est survenu chez 102 (31 %) des patients qui avaient reu le traitement actif et chez 92 (28 %)
de ceux auxquels le placebo avait t assign (rapport de risques : 1,13 ; intervalle de confiance [IC] 95 % : 0,85 1,50 ;
p = 0,51). Lvnement cible secondaire sest produit chez 83 (25 %) des patients du groupe de traitement actif et chez 98 (30 %)
des sujets du groupe placebo (rapport de risques : 0,80 ; IC 95 % : 0,60 1,07 ; p = 0,13).
ConclusionsLaugmentation des apports en acide folique et en vitamines B12 et B6 na pas diminu la mortalit globale et na pas
eu dinfluence significative sur le risque dvnements cardiovasculaires chez les patients atteints dinsuffisance rnale terminale.
Registre des Essais cliniquesURL : www.anzctr.org.au. Identifiant unique : ACTRN12609000911291. URL : www.cochranerenal.org. Identifiant unique : CRG010600027.
(Traduit de langlais : B Vitamins and the Risk of Total Mortality and Cardiovascular Disease in End-Stage Renal Disease Results
of a Randomized Controlled Trial. Circulation. 2010;121:14321438.)
16:33:15:11:10
Page 73